Tags

Type your tag names separated by a space and hit enter

Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial.
Aliment Pharmacol Ther 2007; 26(3):475-86AP

Abstract

BACKGROUND

Health-related quality of life (HRQoL) has been rarely evaluated as a primary endpoint in the assessment of the effect of probiotics on the irritable bowel syndrome (IBS).

AIM

To study the effects of fermented milk containing Bifidobacterium animalis DN-173 010 and yoghurt strains on the IBS in a multicentre, double-blind, controlled trial.

METHODS

A total of 274 primary care adults with constipation-predominant IBS (Rome II) were randomized to consume for 6 weeks either the test fermented milk or a heat-treated yoghurt (control). HRQoL and digestive symptoms were assessed after 3 and 6 weeks on an intention-to-treat population of 267 subjects.

RESULTS

The HRQoL discomfort score, the primary endpoint, improved (P < 0.001) in both groups at weeks 3 and 6. The responder rate for the HRQoL discomfort score was higher (65.2 vs. 47.7%, P < 0.005), as was the decrease in bloating score [0.56 +/- (s.d.)1.01 vs. 0.31 +/- 0.87, P = 0.03], at week 3 in the test vs. the control group. In those subjects with <3 stools/week, stool frequency increased (P < 0.001) over 6 weeks in the test vs. control group.

CONCLUSIONS

This study suggests a beneficial effect of a probiotic food on discomfort HRQoL score and bloating in constipation-predominant IBS, and on stool frequency in subjects with <3 stools/week.

Authors+Show Affiliations

Danone Research, Route Départementale 128, 91767 Palaiseau, France. denis.guyonnet@danone.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17635382

Citation

Guyonnet, D, et al. "Effect of a Fermented Milk Containing Bifidobacterium Animalis DN-173 010 On the Health-related Quality of Life and Symptoms in Irritable Bowel Syndrome in Adults in Primary Care: a Multicentre, Randomized, Double-blind, Controlled Trial." Alimentary Pharmacology & Therapeutics, vol. 26, no. 3, 2007, pp. 475-86.
Guyonnet D, Chassany O, Ducrotte P, et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther. 2007;26(3):475-86.
Guyonnet, D., Chassany, O., Ducrotte, P., Picard, C., Mouret, M., Mercier, C. H., & Matuchansky, C. (2007). Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Alimentary Pharmacology & Therapeutics, 26(3), pp. 475-86.
Guyonnet D, et al. Effect of a Fermented Milk Containing Bifidobacterium Animalis DN-173 010 On the Health-related Quality of Life and Symptoms in Irritable Bowel Syndrome in Adults in Primary Care: a Multicentre, Randomized, Double-blind, Controlled Trial. Aliment Pharmacol Ther. 2007 Aug 1;26(3):475-86. PubMed PMID: 17635382.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. AU - Guyonnet,D, AU - Chassany,O, AU - Ducrotte,P, AU - Picard,C, AU - Mouret,M, AU - Mercier,C-H, AU - Matuchansky,C, PY - 2007/7/20/pubmed PY - 2007/12/15/medline PY - 2007/7/20/entrez SP - 475 EP - 86 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 26 IS - 3 N2 - BACKGROUND: Health-related quality of life (HRQoL) has been rarely evaluated as a primary endpoint in the assessment of the effect of probiotics on the irritable bowel syndrome (IBS). AIM: To study the effects of fermented milk containing Bifidobacterium animalis DN-173 010 and yoghurt strains on the IBS in a multicentre, double-blind, controlled trial. METHODS: A total of 274 primary care adults with constipation-predominant IBS (Rome II) were randomized to consume for 6 weeks either the test fermented milk or a heat-treated yoghurt (control). HRQoL and digestive symptoms were assessed after 3 and 6 weeks on an intention-to-treat population of 267 subjects. RESULTS: The HRQoL discomfort score, the primary endpoint, improved (P < 0.001) in both groups at weeks 3 and 6. The responder rate for the HRQoL discomfort score was higher (65.2 vs. 47.7%, P < 0.005), as was the decrease in bloating score [0.56 +/- (s.d.)1.01 vs. 0.31 +/- 0.87, P = 0.03], at week 3 in the test vs. the control group. In those subjects with <3 stools/week, stool frequency increased (P < 0.001) over 6 weeks in the test vs. control group. CONCLUSIONS: This study suggests a beneficial effect of a probiotic food on discomfort HRQoL score and bloating in constipation-predominant IBS, and on stool frequency in subjects with <3 stools/week. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/17635382/full_citation L2 - https://doi.org/10.1111/j.1365-2036.2007.03362.x DB - PRIME DP - Unbound Medicine ER -